Bright Green has signed a letter of intent to supply its DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations as well as psychedelic molecules currently under investigation for clinical use. This completely homegrown agreement signals Bright Green’s ability and commitment to supply US pharmaceutical partners with high quality organic materials. As part of the supply agreement proposed in the LOI, Benuvia intends to leverage Bright Green’s unique position to produce Schedule I & II raw materials in full compliance with Good Agricultural and Collection Practices, Good Manufacturing Practices, and the DEA, all within the USA, to produce domestically manufactured cGMP pharmaceutical-grade Active Pharmaceutical Ingredients for US and global markets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BGXX:
- BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA PHARMACEUTICALS. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY LEADING AND DEA-APPROVED SCH I & II DRUG FACILITY.
- BRIGHT GREEN ANNOUNCES IT HAS OBTAINED A $3.5 MILLION FUNDING COMMITMENT UNDER AN EXISTING LINE OF CREDIT AND HAS ENGAGED AN INVESTMENT BANK TO SEEK A $15.0 MILLION DEBT FINANCING TO MOVE FORWARD WITH COMMERCIALIZATION.
Questions or Comments about the article? Write to editor@tipranks.com